HIV-1 Envelope glycoprotein-derived peptide–MHC class I complex (HIV-1 Env pMHC-I)

The HIV-1 Envelope glycoprotein (Env) is a primary target for the immune system, synthesized as a gp160 precursor and cleaved into gp120 and gp41 subunits. During HIV infection, these proteins are processed intracellularly into short peptides that are subsequently loaded onto Major Histocompatibility Complex class I (MHC-I) molecules and presented on the surface of infected cells. These peptide–MHC (pMHC) complexes act as specific molecular signatures that allow CD8+ T-cells to identify and destroy virally infected cells. In therapeutic development, Env-derived pMHC complexes are utilized as targets for high-affinity T-cell receptor (TCR) based therapies and TCR-like antibodies, which aim to overcome the limitations of the natural immune response. These strategies are particularly relevant for 'shock and kill' approaches intended to eradicate the latent HIV reservoir by forcing the expression of viral antigens. However, the high mutation rate of the HIV-1 Env gene poses a significant challenge, as it can lead to the loss of pMHC recognition and subsequent viral escape.

Other names

HIV-1 Env peptide-HLA complexEnv-pMHCHIV-1 gp120/gp41 peptide-MHC class I complexHIV-1 Envelope peptide-MHC complex

Therapeutic agents target these complexes to redirect cytotoxic T-lymphocytes (CTLs) or other effector cells to recognize and eliminate HIV-infected cells by binding specifically to the viral peptide presented within the MHC groove.